• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    KalVista Pharmaceuticals Announces Proposed Offering of $110.0 Million of Convertible Senior Notes

    9/24/25 4:01:00 PM ET
    $KALV
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $KALV alert in real time by email

    KalVista Pharmaceuticals, Inc. ("KalVista") (NASDAQ:KALV) announced today that it intends to offer, subject to market conditions and other factors, $110.0 million aggregate principal amount of Convertible Senior Notes due 2031 (the "notes") in a private placement to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). KalVista also intends to grant the initial purchasers of the notes an option to purchase, for settlement within a 13-day period from, and including, the date on which the notes are first issued, up to an additional $15.0 million aggregate principal amount of notes.

    The notes will be senior, unsecured obligations of KalVista, and interest will be payable semi-annually in arrears. The notes will mature on October 1, 2031, unless earlier converted, repurchased or redeemed in accordance with the terms of the notes. Prior to 5:00 p.m., New York City time, on the business day immediately preceding July 31, 2031, the notes will be convertible at the option of holders of the notes only upon satisfaction of certain conditions and during certain periods, and thereafter, the notes will be convertible at the option of holders at any time until 5:00 p.m., New York City time, on the second scheduled trading day immediately preceding the maturity date, regardless of whether such conditions have been met. Upon conversion, the notes may be settled in shares of KalVista's common stock, cash or a combination of cash and shares of KalVista's common stock, at the election of KalVista. Prior to October 1, 2028, the notes will not be redeemable. On or after October 5, 2028, and prior to July 1, 2031, KalVista may redeem for cash all or part of the notes, at its option, subject to a partial redemption limitation, if the last reported sale price of KalVista's common stock has been at least 130% of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which KalVista provides notice of redemption.

    Holders of the notes will have the right to require KalVista to repurchase for cash all or a portion of their notes at 100% of their principal amount, plus any accrued and unpaid interest, upon the occurrence of a fundamental change (as defined in the indenture relating to the notes). KalVista will also be required to increase, in certain circumstances, the conversion rate for holders who convert their notes in connection with certain fundamental changes occurring prior to the maturity date or convert their notes called (or deemed called) for redemption following delivery by KalVista of a notice of redemption.

    The interest rate, initial conversion rate, offering price and other terms are to be determined upon pricing of the notes.

    KalVista expects to use the net proceeds from the contemplated offering for working capital and other general corporate purposes, including the commercialization of EKTERLY. KalVista may also use a portion of the net proceeds from the contemplated offering for investments in and acquisitions of other companies, products or technologies in the future. However, KalVista has no commitments or specific plans with respect to any such investments in and acquisitions of other companies, products or technologies at this time.

    This announcement is neither an offer to sell nor a solicitation of an offer to buy any of these securities (including the shares of KalVista's common stock, if any, into which the notes are convertible) and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale is unlawful. Any offers of the notes will be made only by means of a private offering memorandum.

    The notes will be offered only to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act. The notes and any shares of KalVista's common stock issuable upon conversion of the notes have not been and will not be registered under the Securities Act, or any state securities laws and may not be offered or sold in the United States absent registration or an applicable exemption from such registration requirements.

    Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended, that involve risks and uncertainties, including, without limitation, statements regarding KalVista's proposed offering of the notes and the terms thereof and expected use of net proceeds from the offering. Statements containing words such as "could," "believe," "expect," "intend," "will," or similar expressions constitute forward-looking statements. Factors that may contribute to such differences include, but are not limited to, risks related to whether KalVista will consummate the offering of the notes on the expected terms, or at all, the anticipated principal amount of the notes, which could differ based upon market conditions, the expected use of the net proceeds from the offering, which could change as a result of market conditions or for other reasons, prevailing market and other general economic, industry or political conditions in the United States or internationally, and whether KalVista will be able to satisfy the conditions required to close any sale of the notes. The foregoing list of risks and uncertainties is illustrative, but is not exhaustive. For information about other potential factors that could affect KalVista's business and financial results, please review the "Risk Factors" described in KalVista's Annual Report on Form 10-K for the year ended April 30, 2025 filed with the Securities and Exchange Commission (the "SEC") on July 10, 2025 and in KalVista's other filings with the SEC. Except as may be required by law, KalVista does not intend, and undertakes no duty, to update this information to reflect future events or circumstances.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250924848884/en/

    Investors:

    Ryan Baker

    Head, Investor Relations

    (617) 771-5001

    [email protected]

    Media:

    Molly Cameron

    Director, Corporate Communications

    (857) 356-0164

    [email protected]

    Get the next $KALV alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $KALV

    DatePrice TargetRatingAnalyst
    1/31/2025$19.00Mkt Outperform
    JMP Securities
    1/7/2025$30.00Buy
    TD Cowen
    12/18/2024$22.00Buy
    BofA Securities
    3/11/2022$48.00 → $42.00Buy
    Needham
    12/10/2021$50.00 → $48.00Buy
    Needham
    More analyst ratings

    $KALV
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Venrock Healthcare Capital Partners Iii, L.P. bought $235,500 worth of shares (25,000 units at $9.42) (SEC Form 4)

    4 - KalVista Pharmaceuticals, Inc. (0001348911) (Issuer)

    4/11/25 5:22:07 PM ET
    $KALV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Venrock Healthcare Capital Partners Iii, L.P. bought $1,498,661 worth of shares (161,700 units at $9.27) (SEC Form 4)

    4 - KalVista Pharmaceuticals, Inc. (0001348911) (Issuer)

    2/14/25 7:45:15 PM ET
    $KALV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Venrock Healthcare Capital Partners Iii, L.P. bought $967,145 worth of shares (104,489 units at $9.26) (SEC Form 4)

    4 - KalVista Pharmaceuticals, Inc. (0001348911) (Issuer)

    2/11/25 7:51:08 PM ET
    $KALV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KALV
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    KalVista Pharmaceuticals to Present New EKTERLY® (sebetralstat) Data at the 20th German Allergy Congress

    KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) today announced the acceptance of six abstracts for ePoster presentation at the 20th German Allergy Congress taking place in Düsseldorf, Germany from October 2–4, 2025. Details are as follows: Thursday, October 2 at 4:00–5:15 pm CEST: Time to End of Progression of Hereditary Angioedema Attacks Treated with Sebetralstat: Markus Magerl, Inmaculada Martinez-Saguer, William R. Lumry, John Anderson, Jonathan A. Bernstein, Mauro Cancian, Danny M. Cohn, Henriette Farkas, Henry Li, James Hao, Michael Smith, Paolo Bajcic, Paul Audhya, Petra Staubach, Emel Aygören-Pürsün. Sebetralstat for On-demand Treatment of Hereditary Angioedema Attacks in E

    9/26/25 7:00:00 AM ET
    $KALV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    KalVista Prices Upsized Offering of $125.0 Million of 3.250% Convertible Senior Notes Due 2031

    KalVista Pharmaceuticals, Inc. ("KalVista") (NASDAQ:KALV), announced today the pricing of its offering of $125.0 million aggregate principal amount of 3.250% Convertible Senior Notes due 2031 (the "notes") in a private placement to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). The aggregate principal amount of the offering was increased from the previously announced offering size of $110.0 million. KalVista also granted the initial purchasers of the notes an option to purchase, for settlement within a 13-day period from, and including, the date on which the notes are first issued, u

    9/24/25 10:52:00 PM ET
    $KALV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    KalVista Pharmaceuticals Announces Proposed Offering of $110.0 Million of Convertible Senior Notes

    KalVista Pharmaceuticals, Inc. ("KalVista") (NASDAQ:KALV) announced today that it intends to offer, subject to market conditions and other factors, $110.0 million aggregate principal amount of Convertible Senior Notes due 2031 (the "notes") in a private placement to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). KalVista also intends to grant the initial purchasers of the notes an option to purchase, for settlement within a 13-day period from, and including, the date on which the notes are first issued, up to an additional $15.0 million aggregate principal amount of notes. The note

    9/24/25 4:01:00 PM ET
    $KALV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KALV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CHIEF EXECUTIVE OFFICER Palleiko Benjamin L converted options into 15,625 shares and sold $115,537 worth of shares (7,294 units at $15.84), increasing direct ownership by 2% to 395,189 units (SEC Form 4)

    4 - KalVista Pharmaceuticals, Inc. (0001348911) (Issuer)

    9/9/25 7:02:04 PM ET
    $KALV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Commercial Officer Sweeny Nicole converted options into 5,000 shares and sold $19,862 worth of shares (1,480 units at $13.42), increasing direct ownership by 12% to 32,291 units (SEC Form 4)

    4 - KalVista Pharmaceuticals, Inc. (0001348911) (Issuer)

    8/26/25 8:00:34 PM ET
    $KALV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CHIEF DEVELOPMENT OFFICER Yea Christopher converted options into 3,125 shares and sold $26,223 worth of shares (1,954 units at $13.42), increasing direct ownership by 0.89% to 132,052 units (SEC Form 4)

    4 - KalVista Pharmaceuticals, Inc. (0001348911) (Issuer)

    8/26/25 7:59:05 PM ET
    $KALV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KALV
    SEC Filings

    View All

    KalVista Pharmaceuticals Inc. filed SEC Form 8-K: Other Events

    8-K - KalVista Pharmaceuticals, Inc. (0001348911) (Filer)

    9/29/25 4:27:33 PM ET
    $KALV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by KalVista Pharmaceuticals Inc.

    10-Q - KalVista Pharmaceuticals, Inc. (0001348911) (Filer)

    9/11/25 7:45:42 AM ET
    $KALV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    KalVista Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition

    8-K - KalVista Pharmaceuticals, Inc. (0001348911) (Filer)

    9/11/25 7:24:23 AM ET
    $KALV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KALV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    JMP Securities initiated coverage on KalVista Pharmaceuticals with a new price target

    JMP Securities initiated coverage of KalVista Pharmaceuticals with a rating of Mkt Outperform and set a new price target of $19.00

    1/31/25 7:03:28 AM ET
    $KALV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    TD Cowen initiated coverage on KalVista Pharmaceuticals with a new price target

    TD Cowen initiated coverage of KalVista Pharmaceuticals with a rating of Buy and set a new price target of $30.00

    1/7/25 7:55:33 AM ET
    $KALV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BofA Securities initiated coverage on KalVista Pharmaceuticals with a new price target

    BofA Securities initiated coverage of KalVista Pharmaceuticals with a rating of Buy and set a new price target of $22.00

    12/18/24 7:36:39 AM ET
    $KALV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KALV
    Leadership Updates

    Live Leadership Updates

    View All

    Metagenomi Appoints Laurence Reid, PhD to its Board of Directors

    EMERYVILLE, Calif., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (NASDAQ:MGX) (the "Company"), a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary gene editing toolbox, today announced the appointment of Laurence Reid, PhD, to its Board of Directors. "We are delighted to welcome Dr. Reid to our Board of Directors. Laurence brings a remarkable track record as a company builder and biotech executive, with deep experience across business development, research and development strategy, and organizational growth," said Brian C. Thomas, PhD, CEO and founder of Metagenomi. "Laurence's insight and counsel will be invaluable

    8/11/25 4:05:00 PM ET
    $KALV
    $MGX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    KalVista Appoints Jeb Ledell as Chief Operating Officer

    KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), today announced that Jeb Ledell has joined the Company as Chief Operating Officer (COO). Mr. Ledell is an accomplished public company COO with a track record of driving operational excellence and strategic growth within the biotechnology industry. "I am pleased to welcome Jeb to KalVista at this key time in our evolution. His extensive experience in leading teams and driving efficiency within companies like ours makes him a valued addition to the team as we continue to evolve into a commercial entity," said Ben Palleiko, Chief Executive Officer of KalVista. "I am confident that his proven skills will help us to achieve our goal of delivering s

    12/16/24 7:00:00 AM ET
    $KALV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    KalVista Pharmaceuticals Appoints Laurence Reid, Ph.D., to Board of Directors

    KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), today announced that Laurence Reid, Ph.D., has been appointed to the Company's Board of Directors, effective immediately. Dr. Reid brings more than three decades of experience with a track record of leadership and company-building success. "I am pleased to welcome Dr. Reid, with his deep expertise in high-growth biotech companies, to the KalVista Board of Directors," said Ben Palleiko, Chief Executive Officer of KalVista. "His extensive biopharmaceutical and strategic experience will be a tremendous asset as the Company continues to progress sebetralstat towards global market approval and commercialization." "I am excited to join the KalVist

    11/26/24 7:00:00 AM ET
    $KALV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KALV
    Financials

    Live finance-specific insights

    View All

    KalVista Pharmaceuticals Provides Operational Update and Reports Fiscal Quarter Financial Results

    -EKTERLY® now approved in the US and UK; first and only oral on-demand therapy for acute attacks of hereditary angioedema- -Initiated US EKTERLY launch in July; received 460 patient start forms through August- -European Medicines Agency adopted a positive opinion recommending approval of sebetralstat and confirmed maintenance of orphan designation in EU; decision expected early October- -$191M in cash, providing runway into 2027- -Management to host conference call today at 8:30 a.m. ET- KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), today provided an operational update and released financial results for the fiscal quarter ended July 31, 2025. "This quarter marked a defining mome

    9/11/25 7:00:00 AM ET
    $KALV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    KalVista Pharmaceuticals Announces FDA Approval of EKTERLY® (sebetralstat), First and Only Oral On-demand Treatment for Hereditary Angioedema

    First new on-demand HAE treatment in over a decade, with potential to transform management of the disease Data demonstrated rapid symptom relief and attack resolution regardless of attack severity, location, age, or use of long-term prophylaxis, and well-established safety profile Management to host conference call today at 8:30 a.m. ET KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) today announced that the U.S. Food and Drug Administration (FDA) has approved EKTERLY® (sebetralstat), a novel plasma kallikrein inhibitor, for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged 12 years and older. EKTERLY is the first and only oral on-demand t

    7/7/25 6:30:00 AM ET
    $KALV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    KalVista Pharmaceuticals Reports Phase 3 KONFIDENT Trial Meets All Endpoints for Sebetralstat as First Oral On-demand Therapy for Hereditary Angioedema

    – Sebetralstat 300 mg achieved beginning of symptom relief in 1.6 hours – – Safety profile comparable to placebo – – On track for submission of new drug application to U.S. FDA in the first half of 2024 – – Conference call to discuss trial results today at 8:30 a.m. ET – KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced positive results from the phase 3 KONFIDENT clinical trial demonstrating statistically and clinically significant efficacy of sebetralstat as oral on-demand therapy for hereditary angioedema (HAE). KONFIDENT was the l

    2/13/24 6:30:00 AM ET
    $KALV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KALV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by KalVista Pharmaceuticals Inc.

    SC 13G/A - KalVista Pharmaceuticals, Inc. (0001348911) (Subject)

    11/14/24 4:00:06 PM ET
    $KALV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by KalVista Pharmaceuticals Inc.

    SC 13G/A - KalVista Pharmaceuticals, Inc. (0001348911) (Subject)

    11/14/24 3:57:49 PM ET
    $KALV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by KalVista Pharmaceuticals Inc.

    SC 13G - KalVista Pharmaceuticals, Inc. (0001348911) (Subject)

    11/14/24 12:02:33 PM ET
    $KALV
    Biotechnology: Pharmaceutical Preparations
    Health Care